Diabetes
Video
Obeticholic acid reversed NASH liver fibrosis in phase 3 trial
VIENNA – Phase 3 trial results showed obeticholic acid, already FDA approved, is the first drug to reverse liver fibrosis in NASH patients.
Latest News
Bipartisanship breaks out at House hearing on insulin prices
Lawmakers on both sides of aisle grill insulin manufacturers, PBM leaders on the high cost of insulin.
From the Journals
CV disease and mortality risk higher with younger age of type 2 diabetes diagnosis
In contrast, developing type 2 diabetes over the age of 80 years had little impact on risk.
Latest News
Cigna, Express Scripts to offer $25 cap on 30-day insulin supply
The new patient assistance program would cap out-of-pocket costs for a 30-day supply of insulin at $25.
Feature
Addressing insulin price spikes will require supply chain reform
WASHINGTON – Reforms are needed across the insulin supply chain to resolve the negative impacts of price spiking.
News
New renal, CV disease indication sought for canagliflozin
Canagliflozin is currently indicated for patients with type 2 diabetes but may soon help treat those who also have chronic kidney disease.
Conference Coverage
Hyperglycemia drives leaky gut syndrome, inflammation
MIAMI - HbA1c strongly correlated with the influx of microbial molecules in humans. Correcting hyperglycemia prevented enteric infections and...
News
NIH director updates study enrolling one million participants
NIH director updates study enrolling one million participants
From the Journals
Long-term metformin offsets diabetes in patients with higher glucose/HbA1c, history of gestational diabetes
Long-term metformin was tied to a 41% reduction in diabetes development in women with a history of gestational diabetes.
News
ACC, AHA release first cardiovascular disease primary prevention guideline
“We made the social determinants of health front and center. With many people, clinicians don’t ask whether they have access to healthy foods or a...
From the Journals
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
SGLT2 inhibitors and GLP-1 RAs have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.